London Biotech Biz To Buy Cancer-Focused US Co. For £17M

Thalia Therapeutics said Wednesday that it has agreed to acquire Sanmirna Therapeutics, which specializes in cancer treatments, for up to approximately £16.7 million ($22 million), a move that would transform the...

Already a subscriber? Click here to view full article